The kallikrein-kinin system, but not vascular endothelial growth factor, plays a role in the increased vascular permeability associated with ovarian hyperstimulation syndrome

Journal of Molecular Endocrinology

Volumn 20, Issue 3, 1998, Pages 363-374

  Kobayashi, H ^a   Okada, Y ^a   Asahina, T ^a   Gotoh, J ^a   Terao, T ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; KININ; NEUTRALIZING ANTIBODY; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; KALLIKREIN KININ SYSTEM; NONHUMAN; OVARY CARCINOMA; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; UTERINE TUBE OCCLUSION; VASCULAR ENDOTHELIUM;

ADULT; AGED; AMINO ACID SEQUENCE; ANTIBODIES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITES; BLOTTING, WESTERN; CAPILLARY PERMEABILITY; CHORIONIC GONADOTROPIN; ENDOTHELIAL GROWTH FACTORS; ESTRADIOL; FEMALE; FERTILIZATION IN VITRO; HUMANS; KALLIKREINS; KININS; LYMPHOKINES; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM STAGING; OVARIAN HYPERSTIMULATION SYNDROME; OVARIAN NEOPLASMS; OVULATION INDUCTION; PEPTIDE FRAGMENTS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0031862354     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/jme.0.0200363     Document Type: Article

References (29)

1. Abdalla HI, Baber RJ, Leonard T, Kirkland A, Mitchell A, Power M, Owen E & Studd JW 1989 Timed oocyte collection in an assisted conception programme using GnRH analogue. Human Reproduction 4 927-930.
2. Abramov Y, Barak V, Nisman B & Schenker JG 1997 Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertility and Sterility 67 261-265.
3. Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL & Schnitt SJ 1995 Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Human Pathology 26 86-91.
4. Clements JA, Mukhtar A, Holland AM, Ehrlich AR, & Fuller PJ 1990 Kallikrein gene family expression in the rat ovary: localization to the granulosa cell. Endocrinology 136 1137-1144.
5. Conn G, Soderman DD, Schaeffer M-T, Wile M, Hatcher VB & Thomas KA 1990 Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line. Proceedings of the National Academy of Sciences of the USA 87 1323-1327.
6. Disalvo J, Bayne ML, Conn G, Kwok PW, Trivedi PG, Soderman DD, Palisi TM, Sullivan KA & Thomas KA 1995 Purification and characterization of a naturally occurring vascular endothelial growth factor/placenta growth factor heterodimer. Journal of Biological Chemistry 270 7717-7723.
7. Espey LL, Miller DH & Margolius HS 1986 Ovarian increase in kinin-generating capacity in PMSG/hCG-primed immature rat. American Journal of Pathology 251 E362-E365.
8. Gao X, Greenbaum LM, Mahesh VB & Brann DW 1992 Characterization of the kinin system in the ovary during ovulation in the rat. Biological Reproduction 47 945-951.
9. Gitay-Goren H, Soker S, Vlodavsky I & Neufeld G 1992 The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. Journal of Biological Chemistry 267 6093-6098.
10. Houck KA, Leung DW, Rowland AM, Wine J & Ferrara N 1992 Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. Journal of Biological Chemistry 267 26031-26037.
11. Kondo S, Asano M, Matsuo K, Ohmori I & Suzuki H 1994 Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochimica et Biophysica Acta 1221 211-214.
12. 121) produced by Saccharomyces cerevisiae promotes both angiogenesis and vascular permeability. Biochimica et Biophysica Acta 1243 195-202.
13. Laemmli UK 1970 Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 680-685.
14. Marangoni RA, Antunes E, Brain SD & de Nucci G 1993 Activation by Phoneutria nigriventer (armed spider) venom of tissue kallikrein-kininogen-kinin system in rabbit skin in vivo. British of Journal of Pharmacology 109 539-543.
15. McClure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Hanning Jr RV, Connolly DT & Robertson DM 1994 Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 344 235-236.
16. Nagy JA, Masse EM, Herzberg KT, Meyers MS, Yeo K-T, Yeo T-K, Sioussat TM & Dvorak HF 1995 Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Research 55 360-368.
17. Navot D, Margalioth EJ, Laufer N, Birkenfeld A, Relou A, Rosler A & Schenker JG 1987 Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertility and Sterility 48 57-61.
18. Navot D, Bergh PA & Laufer N 1992 Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertility and Sterility 58 249-261.
19. Neulen J, Yan Z, Paczek S, Weindel K, Keck C, Weich HA, Marme D & Breckwoldt M 1995 Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. Journal of Clinical Endocrinology Metabolism 80 1967-1971.
20. Niedbala MJ & Stein M 1991 Tumor necrosis factor induction of urokinase-type plasminogen activator in human endothelial cells. Biomedicine Biochimica Acta 50 427-436.
21. Niedbala MJ & Stein M 1992 Tumor necrosis factor induction of urokinase-type plasminogen activator mediated proteolysis of extracellular matrix and its antagonism by gamma interferon. Blood 79 678-687.
22. Olson TA, Mohanraj D, Carson LF & Ramakrishnan S 1994 Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Research 54 276-280.
23. Picone R, Kajtaniak EL, Nielsen LS, Behrendt N, Mastronicola MR, Cubellis MV, Stoppelli MP, Pedersen S, Dano K & Blasi F 1989 Regulation of urokinase receptors in monocyte-like U937 cells by phorbol ester phorbol myristate acetate. Journal of Cell Biology 108 693-702.
24. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T & Kerbel RS 1995 Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Research 55 4575-4580.
25. Schenker JG & Weinstein D 1978 Ovarian hyperstimulation syndrome: a current survey. Fertility and Sterility 30 255-268.
26. 2-macroglobulin and the binding is inhibited by heparin. Journal of Biological Chemistry 268 7685-7691.
27. Waltz DA, Sailor LZ & Chapman HA 1993 Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors. Journal of Clinical Investigation 91 1541-1552.
28. Yarali H, Fleige-Zahradka BG, Yuen BH & McComb PF 1993 The ascites in the ovarian hyperstimulation syndrome does not originate from the ovary. Fertility and Sterility 59 657-661.
29. Yeo K-T, Wang HH, Nagy JA, Sioussat TM, Ledbetter SR, Hoogewerf AJ, Zhou Y, Masse EM, Senger DR, Dvorak HF & Yeo T-K 1993 Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Research 53 2912-2918.